iScience Interventional

About iScience Interventional

Established in 1999, iScience Interventional operates within the ophthalmic medical device sector, focusing on the development of microcatheters and imaging technologies. The company was co-founded by Mike Nash, who serves as President and CEO, and Stan Conston, the Vice President of Research & Development and Medical Affairs. Mr. Nash brought extensive experience in ophthalmic products and strategic marketing from his time at institutions like Ioptex Research and American Medical Optics, while Mr. Conston contributed over two decades of life science experience, including involvement in four medical startups and holding numerous patents.

iScience Interventional engineers, manufactures, and markets solutions for what it terms "Interventional Ophthalmology." The firm's target clients are ophthalmologists and surgical centers. Its business model revolves around the sale of specialized, single-use microcatheters and complementary capital equipment. The company pioneered the development of microcatheter and high-resolution imaging systems that allow for site-specific therapies within the eye.

The company's product portfolio is centered around the iCath™ platform, which enables minimally invasive ophthalmic procedures. A key product, the iTrack™ microcatheter, is designed for procedures like canaloplasty, a treatment for glaucoma that reduces intraocular pressure. This is often used with complementary instruments like the iLumin™ light source and the iUltraSound™ imaging system. The business has a history of strategic collaborations, including an investment from Medtronic in 2011 to accelerate commercialization and a supply agreement with a Johnson & Johnson subsidiary to use its microcatheters for delivering cell therapy in clinical trials. In 2014, the canaloplasty business, including the iTRACK 250 catheter, was acquired by Ellex Medical Lasers (now Nova Eye Medical).